Skip to main content
. 2022 May 21;23(10):5793. doi: 10.3390/ijms23105793

Figure 3.

Figure 3

In vitro investigation of the chemotherapy response in SDC3-depleted ovarian cancer cell lines. (A) Response of SDC3 siRNA and control siRNA#1- and #2-treated SKOV3 cells subjected to in vitro treatment with paclitaxel (0–1000 nM), cisplatin (0–8.3 µM) or combinatorial treatment (9:1 paclitaxel/cisplatin (0–1000 nM paclitaxel, 0–114 nM cisplatin) for 72 h. Cell viability was measured by the MTT assay. SDC3-depleted cells showed reduced basal cell viability and under treatment with cisplatin and combined paclitaxel/cisplatin treatment at the indicated concentrations. (B) Response of SDC3 siRNA control and siRNA#1- and #2-treated SKOV3 cells after the normalization against the untreated cells of each condition. (C) Response of SDC3 siRNA and control siRNA#1- and #2-treated SKOV3 cells subjected to in vitro treatment with paclitaxel (0–160 nM), cisplatin (0–3 µM) or combinatorial treatment (9:1 paclitaxel/cisplatin (0–1000 nM paclitaxel, 0–3 µM cisplatin) for 72 h. Cell viability was measured by the MTT assay. SDC3-depleted cells did not show differences in basal cell viability and under treatment with cisplatin and combined paclitaxel/cisplatin treatment at the indicated concentrations. *** = p < 0.001, ** = p < 0.01, * = p < 0.05, # = p < 0.08 (non-significant trend), ns = not significant; n = 8; blue (control), red SDC3 knockdown siRNA#1 and green SDC3 knockdown siRNA#2 lines represent mean values.